|Day's Range||78.88 - 79.16|
|52 Week Range||69.96 - 79.87|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.08%|
After its 2Q17 earnings announcement on July 18, JNJ's share price rose ~1.4% from its closing price of $125.72 on July 17.
Zepatier, a fixed-dose combination of elbasvir and grazoprevir, is indicated for the treatment of patients with HCV genotype 1 and 4 infections.
Yellen testimony is viewed as dovish by market watchers. This could favor these ETFs.